

APPLICANT(S): FRANKEL, Fred R et al.
SERIAL NO.: 10/660,194
FILED: September 11, 2003
Page 3

RECEIVED
CENTRAL FAX CENTER

JUL 10 2008

AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1-20. (Cancelled)

21. (Currently amended) A method of inducing an immune response against a cancer cell in a mammal, the method comprising administering to the said mammal an auxotrophic attenuated strain of *Listeria* comprising an antigen expressed by the said cancer cell, wherein said auxotrophic attenuated strain of *Listeria* comprises a mutation in both the *dal* and *dal* genes of *Listeria*.

22. (Cancelled)

23. (Currently amended) The method of claim 21, wherein the said antigen is expressed from a vector.

24. (Currently amended) The method of claim 21, wherein the said antigen is expressed from the *Listeria* genome.

25. (Currently amended) The method of claim 21, wherein the said auxotrophic attenuated strain of *Listeria* is administered orally, parenterally, intranasally, intramuscularly, intravascularly, intravenously, intrarectally, or intraperitoneally.

26. (Currently amended) The method of claim 21, wherein the said cancer cell is a cervical cancer cell.

27-28. (Cancelled)

APPLICANT(S): FRANKEL, Fred R et al.
SERIAL NO.: 10/660,194
FILED: September 11, 2003
Page 4

29. (Previously Presented) The method of claim 21, wherein said *Listeria* is *L. monocytogenes*.

30. (Not entered) The method of claim 21, wherein said cancer cell is a melanoma cancer cell, a breast cancer cell, or a leukemia cell.

31. (Not entered) The method of claim 26, wherein said antigen is HPV E6, HPV E7, or a combination thereof.

32. (Not entered) The method of claim 21, wherein said antigen is the bcr/abl antigen.

33. (Not entered) The method of claim 21, wherein said antigen is MAGE1, MZ2-E or a combination thereof.

34. (Not entered) The method of claim 21, wherein said antigen is MVC-1, HER-2 or a combination thereof.

35. (Not entered) The method of claim 21, wherein said antigen is expressed as a fusion protein with listeriolysin O (LLO), phosphatidylinositol-specific phospholipase (PI-PLC), or a combination thereof.

36. (Not entered) The method of claim 21, wherein said antigen is expressed from a *Listeria* hly, p60, actA, plcA, mpl, plcB, or inlA gene promoter.

37. (Not entered) The method of claim 21, wherein said immune response is a cytotoxic T cell response.

38. (New) The method of claim 21, wherein said cancer cell is a melanoma cancer cell, a breast cancer cell, or a leukemia cell.

APPLICANT(S): FRANKEL, Fred R et al.
SERIAL NO.: 10/660,194
FILED: September 11, 2003
Page 5

39. (New) The method of claim 26, wherein said antigen is HPV E6 or IIPV E7.
40. (New) The method of claim 21, wherein said antigen is the bcr/abl antigen.
41. (New) The method of claim 21, wherein said antigen is MAGE1 or M72-E.
42. (New) The method of claim 21, wherein said antigen is MVC-1 or IIER-2.
43. (New) The method of claim 21, wherein said antigen is expressed as a fusion protein with listeriolysin O (LLO) or phosphatidylinositol-specific phospholipase (PI-PLC).
44. (New) The method of claim 21, wherein said antigen is expressed from a *Listeria* hly, p60, actA, plcA, mpl, plcB, or inlA gene promoter.